Evidence map›Paper›PMID 33466854›Full record

ArticleJournal of personalized medicine2021

Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia.

Giulia Giacomucci, Salvatore Mazzeo, Silvia Bagnoli, Matteo Casini, Sonia Padiglioni, Cristina Polito, Valentina Berti, Juri Balestrini, Camilla Ferrari, Gemma Lombardi and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05569083 (PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05569083 unknown statusnot on this map

PRedicting the EVolution of SubjectIvE Cognitive Decline to Alzheimer's Disease With Machine Learning

TypeobservationalSponsorAzienda Ospedaliero-Universitaria CareggiRan2020 to 2024Enrolled350ConditionsCognitive Decline, Mild Cognitive Impairment, Alzheimer DiseaseArmsGenetic analysis of APOE and BDNF genes., EEG recording, CSF collection and AD biomarker measurement, Neuropsychological evaluation, Assessment of cognitive reserve, depression, personality traits and leisure activities
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  4. Article
  5. PSEN2 Thr421Met Mutation in a Patient with Early Onset Alzheimer's Disease.International journal of molecular sciences · 2022
    Article
  6. Article
  7. Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Giulia GiacomucciDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0002-8711-331X
Salvatore MazzeoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0001-5985-5060
Silvia BagnoliDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Matteo CasiniFaculty of Medicine and Surgery, University of Florence, Largo Brambilla 3, 50134 Florence, Italy.
Sonia PadiglioniDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Cristina PolitoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Valentina BertiDepartment of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Florence, Via Giovanni Battista Morgagni 50, 50134 Florence, Italy.
Juri BalestriniDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Camilla FerrariDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Gemma LombardiIRCCS Fondazione Don Carlo Gnocchi, Via Scandicci 269, 50143 Florence, Italy.ORCID 0000-0003-2699-0359
Assunta IngannatoDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0003-4955-0321
Sandro SorbiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Benedetta NacmiasDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.
Valentina BessiDepartment of Neuroscience, Psychology, Drug Research and Child Health, University of Florence (NEUROFARBA), Azienda Ospedaliera-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, Italy.ORCID 0000-0002-6176-3584
Azienda Ospedaliero-Universitaria Careggi · ITDon Carlo Gnocchi Foundation · ITUniversity of Florence · IT

Funding

Ateneo dell'Università di Firenze fondi Ateneo 2020, Sorbi and NacmiasFondazione Cassa di Risparmio di Firenze ECRF16 - CONTRIBUTO 2015.0713, SORBI
6 · The paper itself

Abstract

backgroundThe aims of this study were to compare the diagnostic accuracy, sensitivity, specificity, and positive and negative predictive values (PPV, NPV) of different cerebrospinal fluid (CSF) amyloid biomarkers and amyloid-Positron Emission Tomography (PET) in patients with a clinical diagnosis of Alzheimer's disease (AD) and Frontotemporal Dementia (FTD); to compare concordance between biomarkers; and to provide an indication of their use and interpretation.

methodsWe included 148 patients (95 AD and 53 FTD), who underwent clinical evaluation, neuropsychological assessment, and at least one amyloid biomarker (CSF analysis or amyloid-PET). Thirty-six patients underwent both analyses. One-hundred-thirteen patients underwent Apolipoprotein E (ApoE) genotyping.

resultsAmyloid-PET presented higher diagnostic accuracy, sensitivity, and NPV than CSF Aβ

conclusionsCSF Aβ

Indexed as

Alzheimer’s diseaseamyloid-PETCSF biomarkersfrontotemporal dementia

Identifiers

PMID33466854
PMCPMC7830228
OpenAlexW3118850535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.